These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 2596957

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Disposition of the plasmacytomagenic alkane pristane (2,6,10,14-tetramethylpentadecane) in mice.
    Janz S, Shacter E.
    Cancer Biochem Biophys; 1995 Jun; 15(1):25-34. PubMed ID: 8536217
    [Abstract] [Full Text] [Related]

  • 4. Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens.
    Potter M, Wax JS.
    J Natl Cancer Inst; 1983 Aug; 71(2):391-5. PubMed ID: 6576197
    [Abstract] [Full Text] [Related]

  • 5. The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane.
    Avcu F, Ural AU, Yilmaz MI, Ozcan A, Ide T, Kurt B, Yalcin A.
    Eur J Haematol; 2005 Jun; 74(6):496-500. PubMed ID: 15876253
    [Abstract] [Full Text] [Related]

  • 6. Induction of plasma cell tumours with 2,6,10,14-tetramethylpentadecane (pristane) and paraffin oil (paraffinum perliquidum) in BALB/c mice simultaneously exposed to sustained antigenic stimulation with bovine serum albumin (BSA).
    Janz S, Püschel W, Raabe F, Storch H.
    Arch Geschwulstforsch; 1987 Jun; 57(1):25-30. PubMed ID: 3566462
    [Abstract] [Full Text] [Related]

  • 7. Evidence for high purity of a commercial pristane (2,6,10,14-tetramethylpentadecane) preparation used for plasmocytoma induction in BALB/c mice.
    Janz S, Herzschuh R, Storch H.
    Exp Pathol; 1987 Jun; 31(4):253-5. PubMed ID: 3622726
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Specific chromosome translocation in pristane-induced plasmacytomas of NZB mice.
    Oikawa T, Kuzumaki N, Yamada T.
    J Natl Cancer Inst; 1984 Feb; 72(2):347-53. PubMed ID: 6582321
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Translocation and activation of protein kinase C by the plasma cell tumor-promoting alkane pristane.
    Janz S, Gawrisch K, Lester DS.
    Cancer Res; 1995 Feb 01; 55(3):518-24. PubMed ID: 7834620
    [Abstract] [Full Text] [Related]

  • 12. Pristane induces an indomethacin inhibitable inflammatory influx of CD4+ T cells and IFN-gamma production in plasmacytoma-susceptible BALB/cAnPt mice.
    McDonald AH, Degrassi A.
    Cell Immunol; 1993 Jan 01; 146(1):157-70. PubMed ID: 8425224
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Specific pathogen-free BALB/cAn mice are refractory to plasmacytoma induction by pristane.
    Byrd LG, McDonald AH, Gold LG, Potter M.
    J Immunol; 1991 Nov 15; 147(10):3632-7. PubMed ID: 1682379
    [Abstract] [Full Text] [Related]

  • 15. The fluidity of DOPC bilayers and membrane fractions prepared from murine plasmacytoma cells is unchanged after incorporation of pristane (2,6,10,14-tetramethylpentadecane) as assessed by fluorescence polarization analysis.
    Janz S, Krumbiegel M, Gawrisch K.
    Cancer Biochem Biophys; 1992 Nov 15; 13(2):85-92. PubMed ID: 1343851
    [Abstract] [Full Text] [Related]

  • 16. Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane).
    Anderson PN, Potter M.
    Nature; 1969 Jun 07; 222(5197):994-5. PubMed ID: 5789334
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Perturbation of B cell genesis in the bone marrow of pristane-treated mice. Implications for plasmacytoma induction.
    Rico-Vargas SA, Potter M, Osmond DG.
    J Immunol; 1995 Mar 01; 154(5):2082-91. PubMed ID: 7868885
    [Abstract] [Full Text] [Related]

  • 20. Differential susceptibility of BALB/c and DBA/2 cells to plasmacytoma induction in reciprocal chimeras.
    Silva S, Sugiyama H, Babonits M, Wiener F, Klein G.
    Int J Cancer; 1991 Sep 09; 49(2):224-8. PubMed ID: 1879968
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.